(LLY) Eli Lilly - Overview
Stock: Insulin, Diabetes, Oncology, Immunology, Neuroscience
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.74% |
| Yield on Cost 5y | 3.96% |
| Yield CAGR 5y | 15.26% |
| Payout Consistency | 99.5% |
| Payout Ratio | 25.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 70.9% |
| Relative Tail Risk | -13.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.60 |
| Alpha | 14.61 |
| Character TTM | |
|---|---|
| Beta | 0.682 |
| Beta Downside | 0.783 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.48% |
| CAGR/Max DD | 1.36 |
Description: LLY Eli Lilly January 26, 2026
Eli Lilly (NYSE: LLY) is a global, research-driven pharmaceutical company headquartered in Indianapolis. It discovers, develops, and markets prescription medicines across the United States, Europe, China, Japan and other regions, focusing on diabetes, obesity, oncology, immunology and neuroscience.
The core product suite includes a broad insulin portfolio (Basaglar, Humalog, Humulin and related mixes), three blockbuster type-2-diabetes agents (Jardiance, Mounjaro, Trulicity), and the newly launched obesity therapy Zepbound. In oncology, Lilly sells Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio; in immunology it markets Olumiant, Taltz, Omvoh and Ebglyss; and in neuroscience it offers Cymbalta and Emgality for migraine prevention.
Strategic collaborations span biotech and tech partners, including Incyte, Boehringer Ingelheim, Roche/Genentech, AbCellera, Verge Genomics, AdvanCell (targeted-alpha cancer therapies), Chugai (myeloid engager platform), NVIDIA (AI-driven drug discovery), Insilico Medicine and Nimbus Therapeutics (obesity/metabolic pipelines). These alliances aim to accelerate R&D and diversify the pipeline beyond the current product mix.
Recent financial metrics (FY 2023) show total revenue of **$28.5 billion**, a **9 % year-over-year increase**, driven largely by double-digit growth in diabetes and obesity sales. Mounjaro and Zepbound together contributed **≈$4.2 billion** in 2023, and analysts project Zepbound could reach **$2 billion in annual sales by 2025** if market uptake follows early adoption trends. The company’s R&D spend remained steady at **$5.4 billion** (≈19 % of revenue), reflecting its commitment to pipeline expansion amid a competitive biotech environment.
Key sector drivers that could impact Lilly’s outlook include the **global diabetes market’s CAGR of ~6 %** through 2028, rising obesity prevalence (estimated 13 % of U.S. adults), and the **accelerating adoption of AI in drug discovery**, which may shorten development timelines but also raise execution risk.
Consider exploring ValueRay for deeper analytics on Lilly’s valuation sensitivities and peer-relative performance.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 20.64b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 10.62 > 1.0 |
| NWC/Revenue: 33.65% < 20% (prev 9.69%; Δ 23.96% < -1%) |
| CFO/TA 0.14 > 3% & CFO 16.06b > Net Income 20.64b |
| Net Debt (42.51b) to EBITDA (27.94b): 1.52 < 3 |
| Current Ratio: 1.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (898.0m) vs 12m ago -0.57% < -2% |
| Gross Margin: 83.79% > 18% (prev 0.81%; Δ 8298 % > 0.5%) |
| Asset Turnover: 67.32% > 50% (prev 57.22%; Δ 10.09% > 0%) |
| Interest Coverage Ratio: 33.16 > 6 (EBITDA TTM 27.94b / Interest Expense TTM 795.3m) |
Altman Z'' 3.71
| A: 0.19 (Total Current Assets 62.07b - Total Current Liabilities 40.14b) / Total Assets 114.94b |
| B: 0.19 (Retained Earnings 22.25b / Total Assets 114.94b) |
| C: 0.27 (EBIT TTM 26.37b / Avg Total Assets 96.83b) |
| D: 0.0 (Book Value of Equity 0.0 / Total Liabilities 91.08b) |
| Altman-Z'' Score: 3.71 = AA |
What is the price of LLY shares?
Over the past week, the price has changed by +2.03%, over one month by -0.55%, over three months by +13.05% and over the past year by +22.49%.
Is LLY a buy, sell or hold?
- StrongBuy: 16
- Buy: 7
- Hold: 4
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the LLY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1179.5 | 11.5% |
| Analysts Target Price | 1179.5 | 11.5% |
| ValueRay Target Price | 1463.2 | 38.3% |
LLY Fundamental Data Overview February 07, 2026
P/E Forward = 33.67
P/S = 14.0404
P/B = 41.6459
P/EG = 1.0067
Revenue TTM = 65.18b USD
EBIT TTM = 26.37b USD
EBITDA TTM = 27.94b USD
Long Term Debt = 40.87b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.63b USD (from shortTermDebt, two quarters ago)
Debt = 42.51b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 42.51b USD (using Total Debt 42.51b, CCE unavailable)
Enterprise Value = 957.65b USD (915.14b + Debt 42.51b - (null CCE))
Interest Coverage Ratio = 33.16 (Ebit TTM 26.37b / Interest Expense TTM 795.3m)
EV/FCF = 106.2x (Enterprise Value 957.65b / FCF TTM 9.02b)
FCF Yield = 0.94% (FCF TTM 9.02b / Enterprise Value 957.65b)
FCF Margin = 13.84% (FCF TTM 9.02b / Revenue TTM 65.18b)
Net Margin = 31.66% (Net Income TTM 20.64b / Revenue TTM 65.18b)
Gross Margin = 83.79% ((Revenue TTM 65.18b - Cost of Revenue TTM 10.56b) / Revenue TTM)
Gross Margin QoQ = 85.05% (prev 82.91%)
Tobins Q-Ratio = 8.33 (Enterprise Value 957.65b / Total Assets 114.94b)
Interest Expense / Debt = 0.29% (Interest Expense 123.0m / Debt 42.51b)
Taxrate = 19.71% (1.63b / 8.27b)
NOPAT = 21.17b (EBIT 26.37b * (1 - 19.71%))
Current Ratio = 1.55 (Total Current Assets 62.07b / Total Current Liabilities 40.14b)
Debt / Equity = 1.79 (Debt 42.51b / totalStockholderEquity, two quarters ago 23.79b)
Debt / EBITDA = 1.52 (Net Debt 42.51b / EBITDA 27.94b)
Debt / FCF = 4.71 (Net Debt 42.51b / FCF TTM 9.02b)
Total Stockholder Equity = 18.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 21.32% (Net Income 20.64b / Total Assets 114.94b)
RoE = 114.6% (Net Income TTM 20.64b / Total Stockholder Equity 18.01b)
RoCE = 44.79% (EBIT 26.37b / Capital Employed (Equity 18.01b + L.T.Debt 40.87b))
RoIC = 35.54% (NOPAT 21.17b / Invested Capital 59.59b)
WACC = 8.07% (E(915.14b)/V(957.65b) * Re(8.43%) + D(42.51b)/V(957.65b) * Rd(0.29%) * (1-Tc(0.20)))
Discount Rate = 8.43% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.33%
[DCF Debug] Terminal Value 69.92% ; FCFF base≈9.02b ; Y1≈5.92b ; Y5≈2.70b
Fair Price DCF = 10.86 (EV 52.22b - Net Debt 42.51b = Equity 9.72b / Shares 895.0m; r=8.07% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 48.57 | EPS CAGR: 30.61% | SUE: 0.70 | # QB: 0
Revenue Correlation: 95.54 | Revenue CAGR: 27.27% | SUE: 1.69 | # QB: 3
EPS next Quarter (2026-03-31): EPS=7.54 | Chg30d=+0.086 | Revisions Net=+3 | Analysts=13
EPS current Year (2026-12-31): EPS=34.15 | Chg30d=+1.442 | Revisions Net=+2 | Growth EPS=+41.0% | Growth Revenue=+21.8%
EPS next Year (2027-12-31): EPS=41.52 | Chg30d=+1.394 | Revisions Net=+3 | Growth EPS=+21.6% | Growth Revenue=+16.2%